Shaping a European innovation ecosystem: EU-Innovation network multi-stakeholder meeting, Hybrid (Madrid and online), from 26/09/2023 to 26/09/2023

Human medicines European public assessment report (EPAR): Apretude, cabotegravir, HIV Infections, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Radionuclide Imaging;Alzheimer Disease, Date of authorisation: 22/08/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Spondylitis, Ankylosing;Hidradenitis Suppurativa;Psoriasis;Arthritis, Juvenile Rheumatoid;Uveitis, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Arthritis, Juvenile Rheumatoid;Crohn Disease;Skin Diseases, Papulosquamous, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Multiple Sclerosis, Date of authorisation: 30/01/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Omnitrope, somatropin, Turner Syndrome;Prader-Willi Syndrome;Dwarfism, Pituitary, Date of authorisation: 12/04/2006, Revision: 22, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Rozanolixizumab, decision type: , therapeutic area: , PIP number: P/0410/2022

Opinion/decision on a Paediatric investigation plan (PIP): Vumerity,Diroximel fumarate (BIIB098), decision type: , therapeutic area: , PIP number: P/0413/2022